Palmoplantar Pustulosis
What Is Palmoplantar Pustulosis?
Palmoplantar pustulosis is a chronic skin condition in which small pus-filled blisters called pustules repeatedly develop on the palms of the hands and soles of the feet.
Small blisters appear at first and gradually turn into yellow pustules. They then turn brown and dry out, and the skin peels off. Redness and thickened skin are also common. When symptoms are severe, the skin may crack, causing pain when walking or making it difficult to perform tasks with the hands. This can interfere with daily life.
It is relatively common among women in middle age and older and is known to occur frequently in smokers. Symptoms typically improve and worsen repeatedly, and treatment may continue for a long time.
Some patients with palmoplantar pustulosis also develop pustulotic arthro-osteitis, which causes painful inflammation in areas such as the sternum, collarbones, and spine.
Causes of Palmoplantar Pustulosis
The cause of palmoplantar pustulosis is not fully understood, but an abnormal immune response is thought to cause inflammation in the skin. The following factors are known to be associated with its onset or worsening.
Smoking
Palmoplantar pustulosis is common among smokers, and smoking is thought to contribute to its onset and worsening. Quitting smoking is an important part of treatment, and we recommend doing so while receiving medication treatment. However, the rash does not always improve immediately after you stop smoking.
Focal Infections
Chronic infection or inflammation elsewhere in the body, such as tonsillitis, periodontal disease, or tooth decay, may contribute to worsening palmoplantar pustulosis. If you have recurring throat inflammation or need dental treatment, we may recommend an examination by an ear, nose, and throat specialist or a dentist. However, focal infections are not found in every patient.
Metal Allergies
In some patients, an allergy to dental metals or other metals may be involved. We may consider patch testing when necessary, but having a metal allergy does not necessarily mean that dental metal must be removed.
Diagnosing Palmoplantar Pustulosis
We diagnose palmoplantar pustulosis by examining the skin and looking for its characteristic symptom of recurring pustules on the palms and soles. Conditions that can cause similar symptoms include dyshidrosis (dyshidrotic eczema), fungal infections of the hands or feet (athlete’s foot), contact dermatitis, and psoriasis. Because symptoms on the soles may be mistaken for athlete’s foot, we perform a microscopic examination when necessary.
Treatments for Palmoplantar Pustulosis
Treatment for palmoplantar pustulosis combines measures to address aggravating factors, such as smoking and focal infections, with treatment to reduce skin inflammation. If topical medications do not provide enough improvement, we may consider Phototherapy or oral medications.
Topical Treatment
Topical Corticosteroids
Topical corticosteroids reduce inflammation and are a standard treatment for palmoplantar pustulosis. Because the skin on the palms and soles is thick, we may use a high-potency topical corticosteroid, such as clobetasol propionate ointment. We adjust the potency and frequency of application based on your symptoms. Long-term use may cause side effects such as skin atrophy and infections, so these medications must be used appropriately.
Active Vitamin D3 Topical Medications
We use medications such as Oxarol® (maxacalcitol) ointment. They help normalize skin keratinization and reduce inflammation. They may also be used together with topical corticosteroids. Possible side effects include skin irritation and, depending on the amount used, hypercalcemia.
Moisturizers
Palmoplantar pustulosis can cause the skin to thicken, dry out, and crack. Moisturizers do not reduce the inflammation itself, but we use them together with other treatments to improve dryness and cracking.
Phototherapy
We may use Phototherapy for palmoplantar pustulosis that does not improve enough with topical medications. Ultraviolet light helps suppress excessive immune responses in the skin. Tamachi Station Dermatology Clinica Riviera Shibaura has two types of ultraviolet light treatment equipment.
Excimer Light (FlexSys Fit 100)
Excimer light is a treatment device that delivers ultraviolet light at 308 nm. It can precisely treat rashes in limited areas, such as the palms and soles. Because treatment can minimize exposure to healthy skin, it is suitable for conditions with localized lesions, such as palmoplantar pustulosis.
Narrowband UVB (Daavlin 7)
This treatment delivers ultraviolet light at approximately 311–313 nm. The device is used for skin conditions affecting large areas and may also be used for palmoplantar pustulosis. Phototherapy usually requires repeated sessions to assess its effectiveness. We adjust the frequency of visits according to your symptoms and response to treatment. Side effects include redness, stinging, and pigmentation in the treated area. Over the long term, there is also a risk of photoaging and skin cancer.
Combining Phototherapy With Oral Medication
If topical medications or Phototherapy alone do not provide enough improvement, we may combine them with oral medication. Otezla® (apremilast) and Phototherapy reduce skin inflammation in different ways, so combining them may improve treatment effectiveness. However, there are not yet enough clinical data on the effectiveness of this combination for palmoplantar pustulosis. At our clinic, we select the appropriate treatment for each patient while monitoring skin symptoms and the response to treatment.
Oral Treatment
If topical treatment and Phototherapy do not provide sufficient results, we may consider oral medication.
PDE4 Inhibitor: Otezla® (Apremilast)
Otezla® is an oral medication that regulates excessive immune responses by inhibiting PDE4, an enzyme involved in inflammation. In March 2025, insurance coverage was added for palmoplantar pustulosis that has not responded sufficiently to topical treatment.
In a phase III clinical trial in Japan, improvement was observed as early as 2 weeks after treatment began. At 16 weeks, approximately 68% of patients achieved at least a 50% improvement in skin symptoms (PPPASI-50).
PPPASI is a measure used to assess the severity and extent of rashes caused by palmoplantar pustulosis. PPPASI-50 means that the score improved by at least 50% compared with before treatment.
Otezla® is started at a low dose and gradually increased. It is usually taken twice a day. Common side effects include nausea, diarrhea, headache, and decreased appetite. Changes such as depressed mood also require attention. Depending on your symptoms and treatment history, we may also consider combining it with Phototherapy.
Vitamin A Derivative: Tigason® (Etretinate)
Tigason® is a vitamin A derivative, or retinoid, that helps normalize skin keratinization. It may be used for severe palmoplantar pustulosis when other treatments have not provided sufficient results.
Side effects include dry lips and skin, liver dysfunction, and lipid abnormalities. Because it has a strong risk of causing birth defects, it cannot be used during pregnancy. Contraception is also required for 2 years after women stop taking it and for 6 months after men stop taking it. We consider its use only after carefully assessing possible side effects and the patient’s condition.
Biologics (Injectable Medications)
Biologics may be used for moderate to severe palmoplantar pustulosis that has not responded sufficiently to conventional treatment.
Tremfya® (guselkumab): This injectable medication blocks the action of IL-23, a substance involved in inflammation. It received insurance coverage for palmoplantar pustulosis in 2018.
Lumicef® (brodalumab): This injectable medication acts on the IL-17 receptor and blocks the action of IL-17, which is involved in inflammation. It received insurance coverage for palmoplantar pustulosis in 2023.
Both are intended for patients with moderate to severe disease who have not responded sufficiently to existing treatments. Testing for infections such as tuberculosis is required before starting treatment, and patients must also be monitored for infections and other side effects during treatment. If we believe that biologic treatment is appropriate, we will refer you to a general hospital or university hospital that can provide it.
Frequently Asked Questions About Palmoplantar Pustulosis
Q1.
Is palmoplantar pustulosis contagious?
A
No. Palmoplantar pustulosis is not contagious. The pustules usually contain no bacteria, and the condition is not an infection caused by bacteria or viruses. It therefore cannot spread to another person through contact with the affected area or by sharing towels or a bath.
Q2.
Can palmoplantar pustulosis be completely cured?
A
Palmoplantar pustulosis is a chronic skin condition that repeatedly improves and worsens, but some patients remain symptom-free for long periods. It may improve naturally, but its course varies from person to person and it may continue for several years or longer. Appropriate treatment, quitting smoking, and addressing focal infections aim to improve symptoms and prevent recurrence.
Q3.
Will quitting smoking cure palmoplantar pustulosis?
A
Smoking is one of the important factors associated with the onset and worsening of palmoplantar pustulosis. Quitting may improve symptoms, but it does not always cure the condition. If symptoms continue after you stop smoking, we also use treatments such as topical medications, Phototherapy, and oral medications.
Q4.
Are there other treatments if topical medications do not work?
A
Yes. If topical medications do not provide enough improvement, options include Phototherapy and oral treatment. At our clinic, we offer Phototherapy with excimer light and narrowband UVB. Oral treatment with Otezla® (apremilast), which received insurance coverage for palmoplantar pustulosis in 2025, is also an option. We recommend an appropriate treatment based on your symptoms and treatment history.
Q5.
Is Phototherapy for palmoplantar pustulosis covered by insurance?
A
Yes. Phototherapy with excimer light or narrowband UVB for palmoplantar pustulosis is covered by insurance. Treatment is usually given approximately 1–2 times per week. We adjust the exposure level and frequency of visits while monitoring your skin and response to treatment. Multiple sessions are often needed before results appear, and treatment may be combined with topical or oral medication depending on your symptoms.